An Open Label, Phase 2 Trial Comparing Sorafenib And TACE in Advanced Hepatocellular Carcinoma With Portal Vein Invasion.
Phase of Trial: Phase II
Latest Information Update: 05 May 2016
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms STAP
- 07 Jun 2017 Biomarkers information updated
- 05 May 2016 Last checked against ClinicalTrials.gov record.
- 28 Apr 2016 Status changed from recruiting to discontinued.